Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2016 - 2025)

Ironwood Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $460000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 5.15% year-over-year to $460000.0; the TTM value through Dec 2025 reached $1.9 million, down 6.46%, while the annual FY2025 figure was $1.1 million, 8.33% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $460000.0 at Ironwood Pharmaceuticals, down from $475000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $513000.0 in Q1 2024 and bottomed at $270000.0 in Q2 2023.
  • The 5-year median for Depreciation & Amortization (CF) is $435000.0 (2021), against an average of $420400.0.
  • The largest annual shift saw Depreciation & Amortization (CF) plummeted 80.34% in 2021 before it skyrocketed 87.41% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $359000.0 in 2021, then decreased by 5.29% to $340000.0 in 2022, then skyrocketed by 50.59% to $512000.0 in 2023, then dropped by 5.27% to $485000.0 in 2024, then fell by 5.15% to $460000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Depreciation & Amortization (CF) are $460000.0 (Q4 2025), $475000.0 (Q3 2025), and $467000.0 (Q2 2025).